Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Advanced Therapy Medicinal Product (ATMP) Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
Inflammopharmacology. 2023 Feb;31(1):145-169. doi: 10.1007/s10787-022-01115-7. Epub 2023 Jan 7.
Cell-derived exosomes have opened new horizons in modern therapy for advanced drug delivery and therapeutic applications, due to their key features such as low immunogenicity, high physicochemical stability, capacity to penetrate into tissues, and the innate capacity to communicate with other cells over long distances. Exosome-based liquid biopsy has been potentially used for the diagnosis and prognosis of a range of disorders. Exosomes deliver therapeutic agents, including immunological modulators, therapeutic drugs, and antisense oligonucleotides to certain targets, and can be used as vaccines, though their clinical application is still far from reality. Producing exosomes on a large-scale is restricted to their low circulation lifetime, weak targeting capacity, and inappropriate controls, which need to be refined before being implemented in practice. Several bioengineering methods have been used for refining therapeutic applications of exosomes and promoting their effectiveness, on the one hand, and addressing the existing challenges, on the other. In the short run, new diagnostic platforms and emerging therapeutic strategies will further develop exosome engineering and therapeutic potential. This requires a thorough analysis of exosome engineering approaches along with their merits and drawbacks, as outlined in this paper. The present study is a comprehensive review of novel techniques for exosome development in terms of circulation time in the body, targeting capacity, and higher drug loading/delivery efficacies.
细胞衍生的外泌体因其低免疫原性、高物理化学稳定性、能够穿透组织以及与其他细胞进行长距离通讯的固有能力等关键特性,为先进药物输送和治疗应用的现代治疗开辟了新的前景。基于外泌体的液体活检已被潜在地用于一系列疾病的诊断和预后。外泌体可以将治疗剂(包括免疫调节剂、治疗药物和反义寡核苷酸)递送到特定的靶标,并可用作疫苗,尽管它们的临床应用还远未实现。大规模生产外泌体受到其低循环寿命、弱靶向能力和不适当的控制的限制,在实际应用之前需要进行改进。已经使用了几种生物工程方法来改进外泌体的治疗应用并提高其疗效,一方面解决了现有的挑战。从短期来看,新的诊断平台和新兴的治疗策略将进一步发展外泌体工程和治疗潜力。这需要对本文中概述的外泌体工程方法及其优缺点进行彻底分析。本研究全面综述了提高外泌体循环时间、靶向能力和更高药物装载/递送效率的新型外泌体开发技术。